astellas pharma inc
(4503:Tokyo Stock Exchange)
As of 2:00 AM 05/24/13 All times are local (Market data is delayed by at least 15 minutes).
Financial Statements for astellas pharma inc (4503)
Year over year, Astellas Pharma, Inc. has been able to grow revenues from ¥969.4B JPY to ¥1.0T JPY. Most impressively, the company has been able to reduce the percentage of sales devoted to income tax expense from 5.04% to 4.16%. This was a driver that led to a bottom line growth from ¥78.2B JPY to ¥82.9B JPY.
View Income Statement In U.S. Dollar| Currency in Millions of Japanese Yens | As of: | Mar 31 2010 JPY | Mar 31 2011 JPY | Mar 31 2012 JPY | Mar 31 2013 Press Release JPY | 4 Year Trend |
| Revenues | 974,878.0 | 953,947.0 | 969,387.0 | 1,005,611.0 |  | |
| TOTAL REVENUES | 974,878.0 | 953,947.0 | 969,387.0 | 1,005,611.0 | | |
| Cost of Goods Sold | 289,241.0 | 295,972.0 | 318,632.0 | 324,127.0 | | |
| GROSS PROFIT | 685,637.0 | 657,975.0 | 650,755.0 | 681,484.0 | | |
| Selling General & Admin Expenses, Total | 303,630.0 | 321,469.0 | 329,395.0 | 527,617.0 | | |
| R&D Expenses | 195,600.0 | 217,325.0 | 189,840.0 | -- | | |
| OTHER OPERATING EXPENSES, TOTAL | 499,230.0 | 538,794.0 | 519,235.0 | 527,617.0 | | |
| OPERATING INCOME | 186,407.0 | 119,181.0 | 131,520.0 | 153,867.0 | | |
| Interest Expense | -- | -- | -123.0 | -271.0 | | |
| Interest and Investment Income | 3,939.0 | 2,337.0 | 2,364.0 | 1,805.0 | | |
| Other Non-Operating Expenses, Total | -2,162.0 | -6,460.0 | 1,345.0 | 1,754.0 | | |
| Other Non-Operating Income (Expenses) | -2,471.0 | 185.0 | 147.0 | 258.0 | | |
| Gain (Loss) on Sale of Investments | 2,700.0 | 1,280.0 | 2,715.0 | 5,428.0 | | |
| Gain (Loss) on Sale of Assets | -- | -978.0 | 4,501.0 | -34,539.0 | | |
| Other Unusual Items, Total | -4,082.0 | -11,879.0 | -15,249.0 | -3,372.0 | | |
| EBT, INCLUDING UNUSUAL ITEMS | 186,802.0 | 103,481.0 | 127,073.0 | 124,672.0 | | |
| Income Tax Expense | 62,606.0 | 35,831.0 | 48,843.0 | 41,821.0 | | |
| Minority Interest in Earnings | -1,939.0 | -- | -- | -- | | |
| Earnings from Continuing Operations | 124,196.0 | 67,650.0 | 78,230.0 | 82,851.0 | | |
| NET INCOME | 122,257.0 | 67,650.0 | 78,230.0 | 82,851.0 | | |
| NET INCOME TO COMMON INCLUDING EXTRA ITEMS | 122,257.0 | 67,650.0 | 78,230.0 | 82,851.0 | | |
| NET INCOME TO COMMON EXCLUDING EXTRA ITEMS | 122,257.0 | 67,650.0 | 78,230.0 | 82,851.0 | | |
| Recently Viewed | |||
| 4503:JP | ¥5,410.00 JPY | -70.00 |  |
| Company | Last | Change |
| Actavis Inc | $127.23 USD | -0.85 |
| Allergan Inc/United States | $98.02 USD | +0.06 |
| Becton Dickinson and Co | $100.83 USD | +0.66 |
| Mylan Inc/PA | $31.18 USD | -0.57 |
| Takeda Pharmaceutical Co Ltd | ¥4,745 JPY | -55.00 |
| View Industry Companies | ||
Industry Analysis
4503
Industry Average
| Valuation | 4503 | Industry Range |
| Price/Earnings | 27.7x |
|
| Price/Sales | 2.3x |
|
| Price/Book | 2.1x |
|
| Price/Cash Flow | 28.2x |
|
| TEV/Sales | 2.0x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
